Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ALAldeyra The logo

Aldeyra The (ALDX)

NASDAQ · Currency in USD
$0.65 ▲ +0.00 (+0.68%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.62 ▼ -0.03 (-4.49%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$0.65
Open
$0.63
Day's Range
$0.60 – $0.65
52 Week Range
$0.60 – $5.93
Volume
821,553
Avg. Volume
1,380,824
Market Cap
$39.19M
Beta (5Y Monthly)
1.20
PE Ratio (TTM)
--
EPS (TTM)
-$0.38
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.67

Profile: Aldeyra The

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6
CEO
Todd C. Brady

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.11 · Revenue est. $2.50M
DateEst.Actual
Aug 6, 2026-$0.09-$0.09Miss
May 7, 2026-$0.13-$0.06Beat
Feb 27, 2026-$0.14-$0.11Beat
Nov 5, 2025-$0.17-$0.13Beat
Aug 7, 2025-$0.21-$0.16Beat
May 14, 2025-$0.25-$0.17Beat

Analyst view

Consensus price target
$9.67 ▲ +1,388.4%
Range $7.00 – $12.00
Rating: Buy
Buy 95% · Hold 5% · Sell 0%

Get free alerts on ALDX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.